---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-106651"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2023-10-04T23:59:59+00:00"
generated_at: "2026-06-10T04:40:24.594064+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Ocular Therapeutix CEO presents OTX-TKI program at EURETINA conference

## Summary
- CEO Antony Mattessich presented on OTX-TKI for wet AMD at EURETINA Innovation Spotlight on Oct 4, 2023.
- Presentation provided an overview of the investigational tyrosine kinase inhibitor therapy for retinal vascular diseases.
- No new clinical data, financial guidance, or material updates were disclosed in the slides.

## SEC filing metadata
- accession: 0001104659-23-106651
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2023-10-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465923106651/0001104659-23-106651-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465923106651/tm2327605d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-106651
- JSON: https://secwatch.observer/filing/0001104659-23-106651.json
- Plain text: https://secwatch.observer/filing/0001104659-23-106651.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.